IMMG — Immage Biotherapeutics Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -8308.18% | ||
| Return on Equity | -21402.81% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Aug | Unit | 2012 | 2013 | 2014 | 2015 | 2016 | 2017E | 2018E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Immage Biotherapeutics Corp. is a biotechnology company. The Company is engaged in developing cancer immunotherapy through development of cutting-edge immunotherapy candidates using bioinformatics and outsourced laboratory resources. It is focused on developing immunotherapy biologics to treat various cancers. The Company develops, markets and licenses its immunotherapy candidate for melanoma-associated antigen-A (MAGE A). The Company plans to focus on the development of immunotherapy for breast and prostate cancer. The Company focuses on developing a fusion/hybrid antigen cancer vaccine that would not only be human leukocyte antigen (HLA) free, but also be effective to all the isomers associated with MAGE A, from 1 to 11, and the identification and development of immunotherapy candidates from its intellectual property library for the preparation for human clinical trials using a viral vector construct.
Directors
- Last Annual
- August 31st, 2016
- Last Interim
- February 28th, 2017
- Incorporated
- June 21st, 2012
- Public Since
- February 13th, 2014
- Sector
- Chemicals
- Industry
- Basic Materials
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 151,744,566
- Address
- 10411 Motor City Dr Ste 750, BETHESDA, 20817-1289
- Web
- Phone
- +1 4439611185
- Auditors
- Malone Bailey, LLP
Upcoming Events for IMMG
Similar to IMMG
Advanced Container Technologies
Pink Sheets on Nasdaq
Alkane
Pink Sheets on Nasdaq
Angstrom Technologies
Pink Sheets on Nasdaq
Asia Carbon Industries
Pink Sheets on Nasdaq
BioLargo
Pink Sheets on Nasdaq
FAQ
As of Today at 21:17 UTC, shares in Immage Biotherapeutics are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Immage Biotherapeutics last closed at $0.00 and the price had moved by over the past 365 days. In terms of relative price strength the Immage Biotherapeutics share price has underperformed the S&P500 Index by -16.07% over the past year.
There is no consensus recommendation for this security.
Immage Biotherapeutics does not currently pay a dividend.
Immage Biotherapeutics does not currently pay a dividend.
Immage Biotherapeutics does not currently pay a dividend.
To buy shares in Immage Biotherapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Immage Biotherapeutics had a market capitalisation of .
Here are the trading details for Immage Biotherapeutics:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: IMMG
Based on an overall assessment of its quality, value and momentum Immage Biotherapeutics is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Immage Biotherapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -9.44%.
As of the last closing price of $0.00, shares in Immage Biotherapeutics were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Immage Biotherapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Immage Biotherapeutics' management team is headed by:
- Anton Dormer - CHM
- Zhi Cong Mou - PRE
- Elton Norman - CFO
- Mahesh Narayanan - COO
- Daniel Achinko - VPR